Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial.

Kun Huang, Yi Zhao, Chunjun Yang, Jianzhong Zhang

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial

In one paragraph

Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kun Huang *Dermatology Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Yi Zhao *Dermatology Department, Beijing Tsinghua Changgung Hospital, Beijing, China.

Chunjun Yang *Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Jianzhong ZhangDermatology Department, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Xeligekimab, a monoclonal antibody targeting interleukin-17A ( Methods: This Results: Xeligekimab produced rapid improvements across all PASI dimensions by week 4, with induration (-60.1%), scaling (-61.9%), and erythema (-50.3%) versus -5.3% to -7.7% for placebo (all Conclusion: Xeligekimab provides rapid symptom resolution across all clinical dimensions, high and sustained achievement of treatment targets, and comprehensive restoration of quality of life. Clinical Trial Registration: https://www.chictr.org.cn, identifier CHICTR2100043223.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedPsoriasisAdultDouble-Blind MethodFemaleHumansInterleukin-17MaleMiddle AgedPatient Reported Outcome MeasuresQuality of LifeSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedInterleukin-17patient-reported outcomesplaque psoriasispost hoc analysistreatment targetsxeligekimab

Identifiers

PMID42827493

DOI10.3389/fimmu.2026.1917350

PMCPMC13630728

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.